The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>
Open accessAbstract
CONTEXT: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial. OBJECTIVE: To determine the efficacy, safety, and tolerability of tarenflurbil. DESIGN, SETTING, AND PATIENTS: A multicenter, randomized, double-blind, placebo-controlled trial enrolling patients with mild AD was conducted at 133 trial sites in the United States between February 21, 2005, and April 30, 2008. Concomitant treatment with cholinesterase inhibitors or memantine was permitted. INTERVENTION: Tarenflurbil, 800 mg, or placebo, administered twice a day. MAIN OUTCOME MEASURES: Co-primary efficacy end points were the change from baseline to month 18 in total score on the subscale of the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog, 80-point version) and Alzheimer Disease Cooperative Studies-activities of daily living (ADCS-ADL) scale. Additional prespecified slope analyses explored the possibility of disease modification. RESULTS: Of the 1684 participants randomized, 1649 were included in the analysis, and 1046 completed the trial. Tarenflurbil had no beneficial effect on the co-primary outcomes (difference in change from baseline to month 18 vs placebo, based on least squares means: 0.1 for ADAS-Cog; 95% CI, -0.9 to 1.1; P = .86 and -0.5 for ADCS-ADL; 95% CI, -1.9 to 0.9; P = .48) using an intent-to-treat analysis. No significant differences occurred in the secondary outcomes. The ADAS-Cog score decreased by 7.1 points over 18 months. The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. CONCLUSION: Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00105547.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite promising preclinical data, unfortunately a phase 3 clinical trial did not demonstrate any benefits on cognition or ADLs over the course of 18 months (Green et al., 2009).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Green et al., 2009
In the citing paper
“A drug intended to modify γ secretase activity similarly failed [256].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [256]
In the citing paper
“Gintonin, a bioactive glycoprotein reduces the formation of A 𝛽, improves learning and memory capacity through the activation of phosphatidic acid receptors involved in hemolysis [26 , 27] .”
From Phytotherapy: A promising approach for the treatment of Alzheimer's disease (2022) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,010
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,851
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,006
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Cited by
Sorted by citations
Items 501–600 of 658
Racial and Ethnic Reporting and Representation in US Alzheimer Clinical Trials
Lin, Z., Sun, R., Ross, J. S., Lau, K., Stumpf, S., & Chen, M. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.2427 · Cited by 3
Current and emerging therapeutic approaches in Alzheimer’s disease
Chauhan, A., Devi, R., Singh, S., Thakur, R., Bhutani, K., Sharma, R., Kumari, A., Kumar, H., Pal, S., & Saini, A. K. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00290-5 · Cited by 3
Sinha, A. K., Moyé, L. A., Piller, L. B., Yamal, J., Barcenas, C. H., Song, J., & Davis, B. R. (2023) · Communication in Statistics- Theory and Methods · doi:10.1080/03610926.2022.2163180 · Cited by 3
Niazi, S. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810211 · Cited by 3
Sharma, P. K., Yadav, M., & Mehta, N. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0755 · Cited by 3
Shah, F. A., Qadir, H., Khan, J., & Faheem, M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.064 · Cited by 3
Progress in the development of anti-amyloid drugs for treatment of Alzheimer’s disease
Shitaka, Y., Mitani, Y., Nagakura, A., Miyake, A., & Matsuoka, N. (2010) · Folia Pharmacologica Japonica · doi:10.1254/fpj.136.15 · Cited by 3
Dementia prevention and cardiovascular risk factors: a mini-review
Suemoto, C. K. (2015) · Principles and Practice of Clinical Research Journal · doi:10.21801/ppcrj.2015.11.3 · Cited by 3
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_139 · Cited by 3
Addressing the Complex Etiology of Alzheimer‘s Disease: the Role of P25/Cdk5
Mungenast, A. E., & Tsai, L. (2011) · Future Neurology · doi:10.2217/fnl.11.22 · Cited by 3
Targeting γ-Secretase for the Treatment of Alzheimer’s Disease
Hall, A., & Velter, A. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.13789-8 · Cited by 3
Fujita, M., Ho, G. J., Takamatsu, Y., Wada, R., Ikeda, K., & Hashimoto, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082849 · Cited by 3
Ravasse, P., Shehadi, T., Sijelmassi, R., Gandon, S., & Delmas, P. (1989) · PubMed · Cited by 3
Ashford, J. W. (2020) · Neurology · doi:10.1212/wnl.0000000000009184 · Cited by 3
Animal models for Alzheimer's disease – the industry perspective
Czech, C., & Grueninger, F. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2013.07.001 · Cited by 3
Talan, J. (2010) · Neurology Today · doi:10.1097/01.nt.0000368615.98068.71 · Cited by 2
Interim Evaluation of Efficacy or Futility in Clinical Trials with Two Co-primary Endpoints
Hamasaki, T., Asakura, K., Evans, S. R., & Ochiai, T. (2016) · SpringerBriefs in statistics · doi:10.1007/978-4-431-55900-9_4 · Cited by 2
Development of early biomarkers of Alzheimer's disease: A precision medicine perspective
Sarkar, S., Das, N., & Sambamurti, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00006-x · Cited by 2
Al‐Nakkash, L., Mason, D., Ismail, N., Bowman, T., Ahlert, J., Rubin, M., Smith, E., Rosander, A., & Broderick, T. L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192114164 · Cited by 2
ADVANCEMENT IN THE TREATMENT OF ALZHEIMER'S DISEASE, 2023
Safdar, A., Ghani, M. U., Sabar, M. F., Khan, M. U., Hussain, M., aziz, K., & Hussain, T. (2024) · International Journal of Pharmacy & Integrated Health Sciences · doi:10.56536/ijpihs.v5i1.114 · Cited by 2
Neurotropic Viruses as Acute and Insidious Drivers of Aging
Rocchi, A. R., Wollebo, H. S., & Khalili, K. (2025) · Biomolecules · doi:10.3390/biom15040514 · Cited by 2
Liu, S., Zhao, Y., Su, X., Zhou, C., Yang, P., Lin, Q., Li, S., Tan, H., Wang, Q., Wang, C., et al. (2020) · Stem Cells International · doi:10.1155/2020/8897494 · Cited by 2
Morelli, L., Perry, G. L., & Tagliavini, F. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/709613 · Cited by 2
Counting what really counts: the irinotecan in recurrent glioblastoma trial
Streiner, D. L., & Streiner, D. L. (2011) · Community Oncology · doi:10.1016/s1548-5315(12)70093-1 · Cited by 2
Chemical Modulators of Protein Misfolding, Neurodegeneration and Tau
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801944-3.00001-1 · Cited by 2
Chuang‐Stein, C., & Kirby, S. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2020.1807404 · Cited by 2
Targeting Transition Metals for Neuroprotection in Alzheimer’s Disease
Ayton, S., Belaidi, A. A., Lei, P., & Bush, A. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00010-7 · Cited by 2
Alzheimer's Disease: Clinical Trials and Future Perspectives
Lee, K. S., & Suh, H. S. (2012) · 대한정신약물학회지 · Cited by 2
Tam, J. H. K., & Pasternak, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00004-5 · Cited by 2
Stress oxydant et maladie d’Alzheimer
Gilbert, T., Drai, J., & Bonnefoy, M. (2013) · Springer eBooks · doi:10.1007/978-2-8178-0443-9_10 · Cited by 2
Aspartic Proteases of Alzheimer’s Disease: β- and γ-Secretases
Wolfe, M. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.10077-x · Cited by 2
Editorial: Current and Emerging Therapeutics in AD
Sabbagh, M. N., & Decourt, B. (2017) · Current Alzheimer Research · doi:10.2174/156720501404170217182758 · Cited by 2
Ganesh, A., & Galetta, S. L. (2020) · Neurology · doi:10.1212/wnl.0000000000009182 · Cited by 2
Wang, D., Ling, Y., Harris, K., Schulz, P. E., Jiang, X., & Kim, Y. (2023) · medRxiv · doi:10.1101/2023.10.27.23297685 · Cited by 3
Modulating membrane-bound enzyme activity with chemical stimuli
Zhou, Z.-L., Huang, Z., Tang, Y.-Y., Zhu, Y., & Li, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116964 · Cited by 1
Li, C., Ma, C., Lin, Y., Yuan, C., Hao, G., Zhang, Z., & Wang, S. (2026) · ChemistrySelect · doi:10.1002/slct.202505652 · Cited by 1
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Tyagi, N., Pal, S., & Bisht, D. (2025) · Springer eBooks · doi:10.1007/978-981-96-6202-9_13 · Cited by 1
Gao, H., Cheng, F., Zhang, Z., Yan, B., Liao, P., Zhang, S., Li, D., Chen, F., & Lei, P. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05320-7 · Cited by 1
Treatment options for Alzheimer’s Disease: An overview of the amyloid, tau, and alternate hypotheses
Eroltu, K. (2023) · Journal of High School Science · doi:10.64336/001c.89250 · Cited by 1
Alzheimer’s Disease Pharmacotherapy: The Potential for Drug Repurposing
Niha, A., & Loewy, Z. G. (2025) · Neuroscience & Medicine · doi:10.4236/nm.2025.164024 · Cited by 1
Ahmad, H. A., Zafar, M., Khan, T., & Khan, M. I. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05505-1 · Cited by 1
Nabi, S. U., Rasool, I., Khan, A., Haq, A. U., Hussain, I., Khan, M. S., Majid, S., Rashid, S., Rashid, S. M., Sehar, N., et al. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-025-01781-w · Cited by 1
Progress and challenges in drug delivery for the treatment of Alzheimer’s disease
Haghighi, F. H., Xie, J., Ebert, E., & Siahaan, T. J. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2663114 · Cited by 1
Belavadi, S., & Kadiri, S. K. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178913 · Cited by 1
Lindemann, L., Lambotte, J., Rothe, J., Messer, J., Diener, C., Pichereau, S., Cantrill, C., Mueggler, T., Honer, M., Beck, J., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1783414 · Cited by 1
Recent advances in drug treatment for A lzheimer's dementia
Loi, S. M., & Chiu, E. Y.-K. (2011) · Asia-Pacific Psychiatry · doi:10.1111/j.1758-5872.2011.00138.x · Cited by 1
Translational Research in Alzheimer’s Disease for Development of Antibody-Based Therapeutics
Yuen, E., Liu, E., & Kinney, G. G. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_14 · Cited by 1
Schwabe, U. (2013) · Springer eBooks · doi:10.1007/978-3-642-37124-0_10 · Cited by 1
Alzheimer’s Disease: A Clinical Perspective
Xu, W., Marseglia, A., Ferrari, C., & Wang, H. (2013) · InTech eBooks · doi:10.5772/54539 · Cited by 2
Thérapeutiques en regard des anomalies physiopathologiques de la maladie d’Alzheimer
Delrieu, J., Piau, A., & Vellas, B. J. (2011) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2011.03.005 · Cited by 1
Viscount, L. (2011) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine) · Cited by 1
Catabolism and Anabolism of Amyloid-β
Hashimoto, S., Nilsson, P., & Saido, T. C. (2015) · Springer eBooks · doi:10.1007/978-4-431-55763-0_19 · Cited by 2
Discovery of Potent Gamma Secretase Modulators for the Treatment of Alzheimer’s Disease
Rynearson, K. D., Tanzi, R. E., & Wagner, S. L. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_19 · Cited by 1
Clinical Issues in Alzheimer Drug Development
Schneider, L. S. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00019-8 · Cited by 1
Natural Intracellular Consequences of Amyloid
D’Andrea, M. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804256-4.00003-6 · Cited by 1
The future of dementia prevention and treatment strategies
直行, 里. (2020) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.57.374 · Cited by 1
DeMaris, A., & Selman, S. H. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7792-1_2 · Cited by 1
Drug Development for Alzheimer’s Disease: An Historical Perspective
Fillit, H. M., & Cummings, J. L. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.003 · Cited by 1
Herbal Components for the Treatment of Alzheimer's Disease
Bisht, T., Sundram, S., Malviya, R., & Pandey, A. (2023) · The Natural Products Journal · doi:10.2174/2210315513666230123111541 · Cited by 1
Quantitative Metabolic MR Imaging of Human Brain Using17O and23Na
Atkinson, I. C., Lu, A., & Thulborn, K. R. (1996) · Wiley eBooks · doi:10.1002/9780470034590.emrstm1284 · Cited by 1
Chemistry of Alzheimer Disease
Sack, G. H. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-378630-2.00032-3 · Cited by 1
Regulación de la plasticidad astrocitaria por ibuprofeno y FGF2
Lichtenstein, M. P. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases)
Pedrini, S., Morici, M., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch14 · Cited by 1
DeMaris, A., & Selman, S. H. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7792-1_9
γ‐Secretase: An Unusual Enzyme with Many Possible Disease Targets, Including Alzheimer's Disease
Lundkvist, J., & Lendahl, U. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527630943.ch12
Cognitive Enhancers and Treatments for Alzheimer's Disease
Devanand, D. P. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch109
Rational Therapeutics for Alzheimer's Disease and Other Dementias
Kowall, N. W. (2011) · Wiley eBooks · doi:10.1002/9781444344110.ch10
Vidal, B. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Downer, B. G. (2014) · UKnowledge (University of Kentucky)
Mattsson, N., Portelius, E., Blennow, K., & Zetterberg, H. (2012) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.75
Kirshner, H. S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-12-201012210-02004
The right to care and the expectations of society—controversial stem cell therapy in Italy
Bifulco, M., & Gazzerro, P. (2013) · EMBO Reports · doi:10.1038/embor.2013.71
La maladie d’Alzheimer : comment évaluer l’impact de la pathologie et des médicaments ?
Delrieu, J., & Vellas, B. J. (2010) · Therapies · doi:10.2515/therapie/2010057
The vasculature in Alzheimer’s disease: a new therapeutic target for an old disease?
Grammas, P. (2011) · Therapy · doi:10.2217/thy.11.68
Cui, W., Choi, T. C., Mak, S., Yu, H., Hu, S., Li, W., Zuo, Z., & Yifan, H. (2012) · InTech eBooks · doi:10.5772/35663
Targeting cytotoxic species in amyloid diseases
Persson, M. (2012)
Future Pharmacological Armamentaria in Management of Alzheimer Disease
Shah, M. H., Shah, H. D., & Chaudhari, V. (2013) · DOAJ (DOAJ: Directory of Open Access Journals)
Tin, G. (2014) · UWSpace (University of Waterloo)
Novel regulation of neuronal genes implicated in Alzheimer disease by microRNA
Long, J. M. (2013) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2052
PEER-REVIEWED CME ARTICLE Medicine's Valuing of "Normal" Cognitive Ability
Hook, C. C., & Havyer, R. D. A. (2015)
Golde, T. E., Lessard, C. B., & Ran, Y. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00005-8
The Current Status of Alzheimer's Disease Treatment
Lanctôt, K. L., Kircanski, I., Chau, S. A., & Herrmann, N. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-5
Sample Size Recalculation in Clinical Trials with Two Co-primary Endpoints
Hamasaki, T., Asakura, K., Evans, S. R., & Ochiai, T. (2016) · SpringerBriefs in statistics · doi:10.1007/978-4-431-55900-9_3
Interim Evaluation of Efficacy in Clinical Trials with Two Co-primary Endpoints
Hamasaki, T., Asakura, K., Evans, S. R., & Ochiai, T. (2016) · SpringerBriefs in statistics · doi:10.1007/978-4-431-55900-9_2
The Interaction Between Gamma-Secretase And Its Inhibitors And Modulators – Structural Insights
Gertsik, N. (2016) · eCommons (Cornell University)
More Clues in the Alzheimer Conundrum
Drachman, D. A. (2010) · Journal watch · doi:10.1056/jn201003090000001
Rehabilitation System to Improve the Extension Lag Applying the Developed Knee Assistive Instrument
Aoki, K., Makino, K., Nakamura, M., Omori, H., Hanagata, Y., Ueda, S., Ishida, K., & Terada, H. (2017) · Transactions of the Society of Instrument and Control Engineers · doi:10.9746/sicetr.53.286
Choosing Metrics Appropriate for Different Stages of Drug Development
Chuang‐Stein, C., & Kirby, S. (2017) · Springer series in pharmaceutical statistics · doi:10.1007/978-3-319-46076-5_6
Nitrate Chimeras: A New Class of Disease Modifying Agents for the Treatment of Alzheimer's Disease
VandeVrede, L. A. (2014) · Figshare
An Introduction to the CNS Section of Volume 7: Recent Approvals and Advances in CNS Drug Discovery
Hall, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803200-8.02004-6
Nanoformulations for Therapeutics
Rao, P., & Stang, C. R. T. (2017) · Springer eBooks · doi:10.1007/978-3-319-63633-7_6
Present and Future Therapies for Alzheimer’s Disease
Nagase, H., & Nakayama, K. (2018) · InTech eBooks · doi:10.5772/intechopen.75449
Mitochondria-Targeted Nanoparticles
Obulesu, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816412-9.00008-2
Alzheimer’s disease pathogenesis and risk factors
Gerulytė, A., & Strumylaitė, L. (2019) · Neurologijos seminarai · doi:10.29014/ns.2019.25
Effects of anle138b treatment on amyloid-β neurotoxicity
Thomas, C. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8233
Nose-to-Brain Drug Delivery Enabled by Nanocarriers
Warnken, Z. N., Lu, Y., Smyth, H. D. C., & Williams, R. O. (2020) · Neuromethods · doi:10.1007/978-1-0716-0838-8_8
(2013) · Questions de personne · doi:10.3917/dbu.vande.2013.01.0367
Schwabe, U. (2012) · Springer eBooks · doi:10.1007/978-3-642-29242-2_10
Current awareness in geriatric psychiatry
(2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2394
Choosing Metrics Appropriate for Different Stages of Drug Development
Chuang‐Stein, C., & Kirby, S. (2021) · Springer series in pharmaceutical statistics · doi:10.1007/978-3-030-79731-7_6
Metadata
- Authors
- Green, R. C.
- Affiliations
- Boston University (US)
- Corresponding author
- Green, Robert C.
- ORCID
- Green, Robert C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-12-16
- Volume
- 302
- Issue
- 23
- Pages
- 2557
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC2902875
- OpenAlex
- W1982816514
- Cited by
- 643
- References
- 44
- Citations by year
- 2026: 11 · 2025: 25 · 2024: 39 · 2023: 22 · 2022: 28 · 2021: 32 · 2020: 43 · 2019: 32 · 2018: 26 · 2017: 40 · 2016: 40 · 2015: 31 · 2014: 44 · 2013: 52 · 2012: 63
- FWCI
- 38.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institute for Health and Care Research
- National Institutes of Health (RR00533, HG02213, AG13846)
- National Institute on Aging (P30AG008051, K24AG027841, P50AG005142, P30AG013846, P30-AG13846))
- National Human Genome Research Institute (R01HG002213, R01 HG02213)
- National Center for Research Resources (M01-RR-00533, M01RR000533)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, mild Alzheimer disease, cognitive decline, activities of daily living, disease modification, ADAS-Cog, drug safety and efficacy, dizziness, anemia, infection
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Cognition Disorders, Double-Blind Method, Enzyme Inhibitors, Female, Flurbiprofen, Humans, Male, Middle Aged, Peptide Fragments, Amyloid beta-Peptides, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
